Markets
BSE See NSE See 27,803.24
92.72 (0.33%)

Aurobindo Pharma Gets USFDA Approval For Generic Diovan HCT

By Shrikant Akolkar | 3/22/2013 3:42 PM Friday

Aurobindo Pharma has reported receiving final approval for the Valsartan and Hydrochlorothiazide tablets (brand name Diovan HCT held by Novartis). The drug is indicated in the treatment of hypertension to lower blood pressure. The market size of this drug is USD 1.7 billion (Rs 9350 crore) as per the company’s BSE filings. Aurobindo has said that the product is ready for launch and that this will happen soon.

Drug major Mylan has already launched an authorised generic version of this drug in USA. We believe that Aurobindo is the first to launch the generic of this drug considering that Mylan’s was an authorised generic.

We spoke to the company spokesperson, who declined to comment on the pricing and market share of the drug. However, he did say that the company expects to see about 3-4 generic players in the market. Considering this, about 20% market share looks achievable for Aurobindo. Since it is the first to launch, there would not be a massive erosion of price initially. However, as the drug has already fallen out of patent cover, new players would try to enter the market as faster as possible. Once other companies start launching their versions of the drug, the price will go down.

Considering 80% price erosion and 10% market share for Aurobindo, it can be estimated that the company may achieve revenues of about Rs 700 crore from the drug. Of course, these numbers are based on the assumption that the company makes the best of this opportunity.

With this approval, Aurobindo Pharma has a total of 181 ANDA approvals from USFDA, of which 156 are final and 25 are tentative approvals.

Find More Articles on: Markets, DSIJ Mindshare, Product, Large Cap

collapse Related Readings collapse

DSIJ
Mindshare

Tata Metaliks QoQ results drop; BSE revises circuit limit

Tata Metaliks QoQ results drop; BSE revises circuit limit

Tata Metaliks, a subsidiary of Tata Steel is a manufacturer of foundry grade pig iron in India. The company has posted its quarter ended June 2016 results with mixed topline and bottomline numbers.

Must watch: Cairn -Vedanta merger by the year end

Must watch: Cairn -Vedanta merger by the year end

Vedanta, Cairn India and Vedanta Resources plc have declared their revised and final terms to the recommended merger between Vedanta and Cairn India. The deal status has come after trading hours on Friday.

Indices close on upper hand;Tata Motors up by 3.2 %

Indices close on upper hand;Tata Motors up by 3.2 %

The Indian markets pulled up after the mid-market session in the end of July's fourth week. Auto and Capital Goods provided handsome support to indices and both were up more than 150 points. The Sensex recovered over 150 points from the day’s low and ended 92 points up at 27803. The Nifty ended 31 points up at 8541.

Axis Bank results fail to impress in Q1FY17

Axis Bank results fail to impress in Q1FY17

Axis Bank post market hours on July 22 has declared its Q1FY17 results. The bank has posted a timid result in this quarter. Bad loans have been the major reason for such devastating results in this quarter.Bank has reported a net profit of Rs 1560 crore in Q1FY17.

Overnight Digest – Stocks to look out for on July 25

Overnight Digest – Stocks to look out for on July 25

The stocks which could witness a significant movement on July 25 are Ponni Sugars (Erode), Bajaj Corp/Canara Bank, Bharti Airtel/Idea Cellular/Reliance Communication, State Bank of India and L&T Finance Holdings.

Bharat Financial Inclusion surges over 11 per cent on superb results

Bharat Financial Inclusion surges over 11 per cent on superb results

Bharat Financial Inclusion, formerly known as SKS Microfinance has posted remarkable financial results in Q1FY17.Total income from operations stands at Rs 368.96 crores. Total income has increased by a whopping 53 per cent as compared to Q1FY16.

Ashok Leyland posts blockbuster earnings in Q1FY17

Ashok Leyland posts blockbuster earnings in Q1FY17

Ashok Leyland has declared its Q1FY17 results on July 21. The company’s revenue has increased by 10.87 per cent to Rs 4259 crore in Q1FY17 as compared to same period in previous financial year. 

Mid-market commentary July 22

Mid-market commentary July 22

Indian markets remained subdued where the benchmark indices, Nifty and Sensex traded absolutely flat. Broader markets outshined the benchmarks where both Midcap and Smallcap increased by 0.68 per cent and 0.72 per cent respectively.

Weak Q1FY17 results fail to dampen Cairn India's spirits

Weak Q1FY17 results fail to dampen Cairn India's spirits

Cairn India has declared its Q1FY17 results on Thursday. The company’s revenue has decreased by 28.24 per cent to Rs 1885 crore in Q1FY17 as compared to same period in previous fiscal year. 

The three musketeers for Mutual Funds

The three musketeers for Mutual Funds

Are you interested in knowing the top three picks by mutual funds in the banking space? These three banks are the hot favourites with the mutual funds as is seen by the amount of money being invested in these stocks, viz., HDFC bank, Axis Bank and ICICI Bank. 

Subscribe to
Newsletter

news letter

More for the early bird.

Get the post-market reports and breakfast news right in your inbox. See latest »

Market
CHIT CHAT

What is your view on markets today?

200  Characters Remaining.
Please LOGIN  to post your comments or Click here to go back.
Nirmal Srinivasan Jul 23 12:05PM
Buy Pennar Ind good profit Target 66rs
king maker Jul 23 11:16AM
hello all, i will come back soon n help u with stocks...just busy with my personal works,will join u soon
Arnab Mandal Jul 22 10:53PM
Buy NBCC. It will get double
Harshil sanghavi Jul 22 03:58PM
mahindra finance will fall by 4-5% tomorrow
Sonal Verma Jul 22 03:49PM
Biocon India bought at Rs. 711.30 and sold at 816.95 Rs.